At GSK, our portfolio and pipeline is focused in developing medicines and vaccines in four core therapeutic areas, which are the areas of human health we focus on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
We also consider opportunities in organic research and business development in other therapeutic areas, where there is a patient need and where the opportunity fits with our focus on human genetics, genomics, and the science of the immune system.
Key
- †
- In-license or other alliance relationship with third party
- ^
- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
- *
- In Phase I/II study
- #
- In Phase II/III study
- 1
- Non-registrational
- 2
- GSK has an exclusive global license option to co-develop and commercialize the candidate
Pipeline updated 30 April 2025
Key
- †
- In-license or other alliance relationship with third party
- ^
- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
- *
- In Phase I/II study
- #
- In Phase II/III study
- 1
- Non-registrational
- 2
- GSK has an exclusive global license option to co-develop and commercialize the candidate
Q4 2024 to Q1 2025
Key
- †
- In-license or other alliance relationship with third party
- ^
- ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
- *
- In Phase I/II study
- #
- In Phase II/III study
- 1
- Non-registrational
- 2
- GSK has an exclusive global license option to co-develop and commercialize the candidate
Pipeline progress
The content of our development pipeline will change over time as new projects progress from research to development and from development to the market.
Phases of clinical development
Our products in development progress through three stages: phase I, phase II and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval. For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.
Brand names are trademarks either owned by and/or licensed to GSK or associated companies. For COVID-19 vaccines, GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations. This information was updated on 30 April 2025.